EGFR-Mutated NSCLC: Are Frontline Combinations the Future?

September 29th 2020

The Impact of Chemotherapy-Induced Myelosuppression

September 16th 2020

Improving Survival in Metastatic Urothelial Cancer

August 26th 2020

Metastatic NSCLC: Recent Developments on ALK, ROS1, and NTRK

August 17th 2020

Improving Management of Relapsed/Refractory Multiple Myeloma

August 10th 2020

Targeting KRAS Mutations: A Novel Approach in Advanced NSCLC

August 3rd 2020

Treatment Options for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

July 17th 2020

I/O-Based Therapy in Non–Small Cell Lung Cancer

July 16th 2020

Management of Drug-Induced Interstitial Lung Disease

June 30th 2020

Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

June 29th 2020

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

June 29th 2020

Inside the Clinic: Graft-versus-Host Disease Best Practices

June 11th 2020

Evidence-Based Treatment of Metastatic Gastric Cancer

June 2nd 2020

Impact of Upcoming Daratumumab Subcutaneous Formulation for Treatment of Multiple Myeloma

May 13th 2020

Management of Tumor Lysis Syndrome

April 29th 2020

Initial Therapy for Advanced Renal Cell Carcinoma

March 31st 2020

Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer

March 30th 2020

Management of Neurofibromatosis Type 1 with Plexiform Neurofibromas (NF1 with PNs)

March 23rd 2020

Early Diagnosis of Myeloma: Guideline Compliant Testing

March 19th 2020

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer

March 18th 2020